WASHINGTON — The Supreme Court has temporarily upheld women’s access to mifepristone, a widely used abortion pill, allowing its availability to continue until at least Thursday. This decision comes as the justices deliberate on potential restrictions that could limit access to the medication, which has been a critical option for those seeking abortions.
Justice Samuel Alito’s order ensures that women can obtain mifepristone through pharmacies or by mail without the necessity of an in-person consultation with a healthcare provider. This ruling effectively pauses the implementation of restrictions imposed by a federal appeals court, maintaining the status quo for the time being. The implications of this decision are significant, as it reflects ongoing legal battles surrounding reproductive rights and access to healthcare, which are likely to influence regulatory frameworks and pharmaceutical sourcing strategies in the future.
Open the full market picture for your next decision →
